Skip to main content
SpringerLink
Log in

Serum Free Indoxyl Sulfate Associated with In-stent Restenosis After Coronary Artery Stentings

  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

Uremic toxins, including P-cresyl sulfate (PCS) and indoxyl sulfate (IS), have been found to participate in the process of atherosclerosis and patient mortality. We aim to discover if uremic toxins are related to in-stent restenosis in patients with coronary artery disease after stent implantation. We enrolled 214 patients who received coronary angioplasty with stenting and follow-up angiography between November 1995 and June 2011 with a total of 293 lesions divided into bare metal stent (BMS) or drug-eluting stent (DES) groups. Patients’ basic information and total and free form IS and PCS were used to correlate with the late loss (LL) and loss index (LI). Significantly higher LL and LI in the BMS group compared with the DES group (1.10 vs. 0.45 mm, p < 0.001, and 0.46 vs. 0.19, p < 0.001, respectively). The unadjusted correlation revealed a positive relationship between log-normalized free IS and LL, LI in the DES group (p = 0.001). After adjustment for multiple variables, the log-normalized free IS still presented as an independent predictor for the LL and LI (p = 0.012 and p = 0.031). Free IS is an independent predictor for coronary restenosis in patients receiving DES implantations. However, among patients undergoing BMS stentings, uremic toxin is not a predictor of the intracoronary restenosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., et al. (2003). Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 108, 2154–2169.

    Article  PubMed  Google Scholar 

  2. Brunet, P., Gondouin, B., Duval-Sabatier, A., Dou, L., Cerini, C., Dignat-George, F., et al. (2011). Does uremia cause vascular dysfunction? Kidney and blood pressure research., 34, 284–290.

    Article  CAS  PubMed  Google Scholar 

  3. Schiffer, E., Liabeuf, S., Lacroix, C., Temmar, M., Renard, C., Monsarrat, B., et al. (2011). Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. Journal of Hypertension, 29, 783–790.

    Article  CAS  PubMed  Google Scholar 

  4. Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., et al. (2009). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clinical journal of the American Society of Nephrology : CJASN., 4, 1551–1558.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Chiu, C. A., Lu, L. F., Yu, T. H., Hung, W. C., Chung, F. M., Tsai, I. T., et al. (2010). Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. The review of diabetic studies : RDS., 7, 275–284.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Niwa, T. (2010). Indoxyl sulfate is a nephro-vascular toxin. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation., 20, S2–S6.

    Article  CAS  Google Scholar 

  7. Wang, C. P., Lu, L. F., Yu, T. H., Hung, W. C., Chiu, C. A., Chung, F. M., et al. (2010). Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis., 211, 579–583.

    Article  CAS  PubMed  Google Scholar 

  8. Fujii, H., Nakai, K., & Fukagawa, M. (2011). Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Therapeutic Apheresis and Dialysis, 15, 125–128.

    Article  CAS  PubMed  Google Scholar 

  9. Jourde-Chiche, N., Dou, L., Cerini, C., Dignat-George, F., & Brunet, P. (2011). Vascular incompetence in dialysis patients–protein-bound uremic toxins and endothelial dysfunction. Seminars in Dialysis, 24, 327–337.

    Article  PubMed  Google Scholar 

  10. Niwa, T. (2011). Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Therapeutic Apheresis and Dialysis, 15, 120–124.

    Article  CAS  PubMed  Google Scholar 

  11. Wu, I. W., Hsu, K. H., Lee, C. C., Sun, C. Y., Hsu, H. J., Tsai, C. J., et al. (2011). p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrology, Dialysis, Transplantation., 26, 938–947.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Sato, B., Yoshikawa, D., Ishii, H., Kikuchi, R., Arima, T., Takeshita, K., et al. (2013). Indoxyl sulfate, a uremic toxin, and carotid intima-media thickness in patients with coronary artery disease. International Journal of Cardiology, 163, 214–216.

    Article  PubMed  Google Scholar 

  13. de Loor, H., Bammens, B., Evenepoel, P., De Preter, V., & Verbeke, K. (2005). Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clinical Chemistry, 51, 1535–1538.

    Article  PubMed  Google Scholar 

  14. Niwa, T., & Ise, M. (1994). Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. The Journal of Laboratory and Clinical Medicine, 124, 96–104.

    CAS  PubMed  Google Scholar 

  15. Dou, L., Jourde-Chiche, N., Faure, V., Cerini, C., Berland, Y., Dignat-George, F., et al. (2007). The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. Journal of Thrombosis and Haemostasis: JTH., 5, 1302–1308.

    Article  CAS  PubMed  Google Scholar 

  16. Dou, L., Bertrand, E., Cerini, C., Faure, V., Sampol, J., Vanholder, R., et al. (2004). The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney International, 65, 442–451.

    Article  CAS  PubMed  Google Scholar 

  17. Yamamoto, H., Tsuruoka, S., Ioka, T., Ando, H., Ito, C., Akimoto, T., et al. (2006). Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney International, 69, 1780–1785.

    Article  CAS  PubMed  Google Scholar 

  18. Schepers, E., Meert, N., Glorieux, G., Goeman, J., Van der Eycken, J., & Vanholder, R. (2007). P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology, Dialysis, Transplantation, 22, 592–596.

    Article  CAS  PubMed  Google Scholar 

  19. Meijers, B. K., Bammens, B., De Moor, B., Verbeke, K., Vanrenterghem, Y., & Evenepoel, P. (2008). Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney International, 73, 1174–1180.

    Article  CAS  PubMed  Google Scholar 

  20. Abbott, J. D., Voss, M. R., Nakamura, M., Cohen, H. A., Selzer, F., Kip, K. E., et al. (2007). Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. Journal of the American College of Cardiology, 50, 2029–2036.

    Article  CAS  PubMed  Google Scholar 

  21. Stettler, C., Wandel, S., Allemann, S., Kastrati, A., Morice, M. C., Schomig, A., et al. (2007). Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 370, 937–948.

    Article  CAS  PubMed  Google Scholar 

  22. Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., et al. (1994). A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. The New England Journal of Medicine., 331, 496–501.

    Article  CAS  PubMed  Google Scholar 

  23. Serruys, P. W., de Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., et al. (1994). A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. The New England Journal of Medicine., 331, 489–495.

    Article  CAS  PubMed  Google Scholar 

  24. Hoffmann, R., Mintz, G. S., Dussaillant, G. R., Popma, J. J., Pichard, A. D., Satler, L. F., et al. (1996). Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation, 94, 1247–1254.

    Article  CAS  PubMed  Google Scholar 

  25. Kearney, M., Pieczek, A., Haley, L., Losordo, D. W., Andres, V., Schainfeld, R., et al. (1997). Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation, 95, 1998–2002.

    Article  CAS  PubMed  Google Scholar 

  26. Kornowski, R., Hong, M. K., Tio, F. O., Bramwell, O., Wu, H., & Leon, M. B. (1998). In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. Journal of the American College of Cardiology, 31, 224–230.

    Article  CAS  PubMed  Google Scholar 

  27. Komatsu, R., Ueda, M., Naruko, T., Kojima, A., & Becker, A. E. (1998). Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation, 98, 224–233.

    Article  CAS  PubMed  Google Scholar 

  28. Hill RA, Boland A, Dickson R, Dundar Y, Haycox A, McLeod C, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii, xi-221.

  29. Lemos, P. A., Hoye, A., Goedhart, D., Arampatzis, C. A., Saia, F., van der Giessen, W. J., et al. (2004). Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) study. Circulation, 109, 1366–1370.

    Article  PubMed  Google Scholar 

  30. Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010). In-stent restenosis in the drug-eluting stent era. Journal of the American College of Cardiology, 56, 1897–1907.

    Article  PubMed  Google Scholar 

  31. Ota, T., Umeda, H., Yokota, S., Miyata, S., Takamura, A., Sugino, S., et al. (2009). Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. American Heart Journal, 158, 92–98.

    Article  CAS  PubMed  Google Scholar 

  32. Wu, I. W., Hsu, K. H., Hsu, H. J., Lee, C. C., Sun, C. Y., Tsai, C. J., et al. (2012). Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients–a prospective cohort study. Nephrology, Dialysis, Transplantation, 27, 1169–1175.

    Article  CAS  PubMed  Google Scholar 

  33. Meijers, B. K., Van Kerckhoven, S., Verbeke, K., Dehaen, W., Vanrenterghem, Y., Hoylaerts, M. F., et al. (2009). The uremic retention solute p-cresyl sulfate and markers of endothelial damage. American Journal of Kidney Diseases, 54, 891–901.

    Article  CAS  PubMed  Google Scholar 

  34. Lin, C. J., Chuang, C. K., Jayakumar, T., Liu, H. L., Pan, C. F., Wang, T. J., et al. (2013). Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients. Archives of Medical Science: AMS., 9, 662–668.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Adijiang, A., Goto, S., Uramoto, S., Nishijima, F., & Niwa, T. (2008). Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrology, Dialysis, Transplantation, 23, 1892–1901.

    Article  CAS  PubMed  Google Scholar 

  36. Niwa, T. (2010). Uremic toxicity of indoxyl sulfate. Nagoya Journal of Medical Science, 72, 1–11.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology and Percutaneous Coronary Intervention Center, Chang Gung Memorial Hospital, Taipei, Taiwan

    Ming-Lung Tsai, I-Chang Hsieh & Chun-Chi Chen

  2. Department of Nephrology, Chang Gung Memorial Hospital, 199 Tung Hwa North Road, Taipei, Taiwan

    Cheng-Chieh Hung

  3. College of Medicine, Chang Gung University, Taoyuan, Taiwan

    Ming-Lung Tsai, I-Chang Hsieh, Cheng-Chieh Hung & Chun-Chi Chen

Authors
  1. Ming-Lung Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I-Chang Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng-Chieh Hung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chun-Chi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chun-Chi Chen.

Additional information

Ming-Lung Tsai and I-Chang Hsieh have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsai, ML., Hsieh, IC., Hung, CC. et al. Serum Free Indoxyl Sulfate Associated with In-stent Restenosis After Coronary Artery Stentings. Cardiovasc Toxicol 15, 52–60 (2015). https://doi.org/10.1007/s12012-014-9270-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-014-9270-2

Keywords

Search

Navigation